<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="64013">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272569</url>
  </required_header>
  <id_info>
    <org_study_id>ISM01</org_study_id>
    <nct_id>NCT02272569</nct_id>
  </id_info>
  <brief_title>STARflo European Safety and Efficacy Study</brief_title>
  <official_title>A Prospective, Non-comparative, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the STARflo Glaucoma Implant in Patients With Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iSTAR Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iSTAR Medical</source>
  <brief_summary>
    <textblock>
      Prospective, Non-comparative, Multi-center clinical trial to evaluate the safety and
      efficacy of the STARflo Glaucoma Implant in patients with refractory open angle glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter clinical trial to assess the efficacy and the safety of
      the STARflo™ Glaucoma Implant.

      Patients will enter the study after providing written informed consent. Patients will be
      screened to confirm that they are eligible for study participation.

      When eligibility has been established using the in/exclusion criteria, surgery will be
      scheduled.

      Pre and post-surgery, patients will be evaluated at scheduled intervals (1 day, 1 week, 1
      month, 3 months, 6 months, 12 months) for a total duration of 12 months following surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute reduction in IOP (mmHg) vs. baseline</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative reduction in IOP (%) vs. baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in IOP lowering medications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>STARflo Glaucoma Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the STARflo Glaucoma Implant by an ab-externo technique with connection from the anterior chamber to the suprachoroidal space</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STARflo Glaucoma Implant</intervention_name>
    <description>Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotics.</description>
    <arm_group_label>STARflo Glaucoma Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Diagnosis of refractory open angle glaucoma

          -  Documented 21 mmHg &lt; IOP ≤ 40 mmHg, under medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claude Maubrey</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor Representative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheng Lim, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Medical Advisor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Claude Maubrey</last_name>
    <phone>+33 778703958</phone>
    <email>marie-claude@istarmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veva De Groot, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Collignon, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MHAT Central Onco Hospital</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukan Mishev, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain Bron, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix-Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69417</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Denis, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHNO des Quinze Vingts</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Baudouin, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerd Auffarth, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Hirneiss, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augenklinik Universitatsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anselm Juenemann, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik fur Augenheilkunde Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milko Iliev, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 25, 2016</lastchanged_date>
  <firstreceived_date>October 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>glaucoma drainage device</keyword>
  <keyword>glaucoma shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
